¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Fractures involving multiple body regions"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • body fat
    üÁö¹æ, ¸öÁö¹æ
  • body fluid
    ü¾×
  • body fluid compartment
    ü¾×±¸È¹
  • body image
    ½Åü»ó
  • body image agnosia
    ÀÚ¼¼ÀνĺҴÉ(Áõ), ÀÚ¼¼½ÇÀÎÁõ
  • body louse
    ¸öÀÌ, ¿Ê´Ï
  • body mass index
    ½Åüºñ¸¸Áö¼ö, ½ÅüÁú·®Áö¼ö
  • body memory
    ½Åü±â¾ï
  • body odor
    üÃë
  • body position
    üÀ§
  • body posture
    üÀ§
  • body section radiography
    ´ÜÃþ¹æ»ç¼±ÃÔ¿µ(¼ú)
  • body stalk
    ¸öÁÙ±â
  • body surface mapping
    üǥ¸éÀüÀ§Áöµµ
  • body temperature
    ü¿Â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • body composition
    ¸öÁ¶¼º
  • body concept
    ½Åü°³³ä
  • body contour
    ÀÎüÀ±°û
  • body contouring
    ¸öÀ±°û¼ºÇü¼ú
  • body ego
    ½ÅüÀÚ¾Æ
  • body fat
    ¸öÁö¹æ, üÁö¹æ
  • body fluid
    ü¾×
  • body heat
    ü¿­
  • body image
    ½Åü»ó, ¸ö¸ð¾ç»ó
  • body louse
    ¸öÀÌ, ¿Ê´Ï
  • body memory
    ½Åü±â¾ï
  • body odor
    üÃë
  • body position
    üÀ§
  • body posture
    üÀ§
  • body stalk
    ¸öÁÙ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • iliac body
    Àå°ñ ¸öü, Àå°ñ ü(íóÍéô÷).
  • iliac body
    Àå°ñ¸öü, Àå°ñü(íóÍéô÷).
  • iliac body
    Àå°ñü(Àå°ñü).
  • immune amboceptor =i. body
    ¾ç¼öü(å»áôô÷).
  • inclusion body
    ºÀÀÔü
  • inclusion body disease
    ºÀÀÔüº´.
  • inclusion body fibromatosis
    ºÀÀÔü ¼¶À¯Á¾Áõ
  • inclusion body myositis
    ºÀÀÔü ±Ù¿°(¡­ÐÉæú)
  • inclusion body, cytoplasmic
    ¼¼Æ÷Áú³» ºÀÀÔü
  • inclusion body, intracytoplasmic
    ¼¼Æ÷³»ºÀÀÔü
  • inferior body of hyoid bone
    ¸ñ»Ô»À¾Æ·¡¸öÅë
  • initial body
    ¿ø½Ãü(ê«ã·ô÷), Ãʱâü(ôøÑ¢ô÷) ¡ì¹ÙÀÌ·¯½ºÀÇ¡í.
  • picture frame vertebral body
    ±×¸²Æ²(¾×ÀÚÇü)Ãßü
  • pineal body
    ¼Û°úü(áæÍýô÷).
  • pineal body
    ¼Û°úü(áæÍýô÷).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • multiple endocrine adenoma
    ´Ù¹ß¼º ³»ºÐºñ¼±Á¾(¡­³»ºÐÇʼ±Á¾).
  • multiple endocrine adenomatosis =MEA
    ´Ù¹ß¼º ³»ºÐºñ¼±Á¾Áõ(ÒýÛ¡àõÒ®ÝÂù²àÍðþñø).
  • multiple endocrine adenomatosis =MEA
    ´Ù¹ß¼º ³»ºÐºñ¼±Á¾Áõ(´Ù¹ß¼º³»ºÐÇʼ±Á¾Áõ).
  • multiple endocrine adenomatosis =mea
    ´Ù¹ß¼º ³»ºÐºñ¼±Á¾Áõ(¡­ñø)
  • multiple endocrine neoplasia
    ´Ù¹ß¼º ³»ºÐºñ ½Å»ý¹°
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ¼±½Å»ý¹°(ãæßæÚª)
  • multiple endocrine neoplasia syndrome
    ´Ù¹ß¼º ³»ºÐºñ¼±Á¾Áõ
  • multiple endocrine neoplasia(MEN)
  • multiple epiphyseal dysplasia
    ¹æ»ç º´¸®´Ù¹ß¼º °ñ´ÜÀÌÇü¼ºÁõ.
  • multiple epiphyseal dysplasia
    ´Ù¹ß¼º °ñ´ÜÀÌÇü¼ºÁõ(ÒýÛ¡àõÍéÓ®ì¶û¡à÷ñø).
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ(Òý Û¡ß¾ù«ðþñø).
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ(ÒýÛ¡ß¾ù«ðþñø)
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ(´Ù¹ß»óÇÇÁ¾Áõ).
  • multiple evanescent white dot syndrome
    ´Ù¹ß¼º¼Ò½Ç¼º¹é¹ÝÁõÈıº
  • multiple excitaiton
    ´ÙÁß ¿©±â
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Body of breast
    Á¥¸öÅë
    [¿¾ ¿ë¾î] À¯µÎü
  • Body of fibula
    Á¾¾Æ¸®»À¸öÅë
    [¿¾ ¿ë¾î] ºñ°ñü
  • Intermediate body
    Áß°£¼Òü
    [¿¾ ¿ë¾î] Áß°£¼Òü
  • Body of vertebra
    ôÃß»À¸öÅë
    [¿¾ ¿ë¾î] Ãßü
  • First polar body
    ù°±ØÃ¼
    [¿¾ ¿ë¾î] ÀÏÂ÷±ØÃ¼
  • Body of mandible
    ÅλÀ¸öÅë
    [¿¾ ¿ë¾î] ÇϾÇü
  • Amygdaloid body
    ÆíµµÃ¼
    [¿¾ ¿ë¾î] ÆíµµÃ¼
  • Branches of amygdaloid body
    ÆíµµÃ¼°¡Áö
    [¿¾ ¿ë¾î] ÆíµµÃ¼Áö
  • Pre-epiglottic adipose body
    Èĵε¤°³¾ÕÁö¹æÃ¼
    [¿¾ ¿ë¾î] Èĵΰ³ÀüÁö¹æÃ¼
  • Body of rib
    °¥ºñ»À¸öÅë
    [¿¾ ¿ë¾î] ´Á°ñü
  • Body of ischium
    ±ÃµÕ»À¸öÅë
    [¿¾ ¿ë¾î] Á°ñü
  • Body of fornix
    ³úȰ¸öÅë
    [¿¾ ¿ë¾î] ³ú±Ãü
  • Body of pubis
    µÎµ¢»À¸öÅë
    [¿¾ ¿ë¾î] Ä¡°ñü
  • Body of incus
    ¸ð·ç»À¸öÅë
    [¿¾ ¿ë¾î] ħ°ñü
  • Body of hyoid bone
    ¸ñ»Ô»À¸öÅë
    [¿¾ ¿ë¾î] ¼³°ñü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MM Multiple Myeloma
MS   1) Mitral Stenosis
  2) Multiple Sclerosis; ´Ù¹ß¼º °æÈ­Áõ
  3) Macro...
MSLT Multiple Sleep Latency Test
MODS Multiple Organ Dysfunction Syndrome
AMBER advanced multiple-beam equalization radiography
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MEA Multiple Endocrine Adenomatosis
MEN Multiple Endocrine Neoplasia
MEN I Multiple Endocrine Neoplasia
MEN 1 Multiple Endocrine Neoplasia Type 1
MEN2a Multiple Endocrine Neoplasia Type 2a
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • body coil
    µ¿Ã¼ ÄÚÀÏ
  • body feeling
    ½Åü ´À³¦
  • body fluid compartment
    ü¾× ºÐȹ, ü¾× ±¸ºÐ
  • body girth
    ½Åü ´ë°æ
  • body height
    ½ÅÀå
    µ¿ÀǾî=body length.
  • body image agnosia
    ½Åü»ó ½ÇÀÎÁõ
  • body language
    ½Åü ¾ð¾î, ½Åü¾î
    ¾ð¾î·Î Ç¥ÇöÇÏÁö ¾Ê°í ¸öÁþÀ̳ª ÇൿÀ¸·Î ¿øÇÏ´Â ¶æÀ» Àü´ÞÇÏ´Â ÀÇ»ç¼ÒÅë¹ýÀÌ´Ù. ÀÏ¸í ¸¸±¹ °øÅë¾î¶ó°íµµ ÇÑ´Ù. ¿¹¸¦ µé¾î ¸ñÀÌ ¸¶¸£¸é ¹° ¸¶½Ã´Â Èä³»¸¦ ³»¸é µÈ´Ù.
  • body mastery
    ½Åü ¼÷´Þ
  • body of hyoid bone
    ¼³°ñ ü
  • body of mandible
    ÇÏ¾Ç °ñü
  • body of metacarpal bones
    ¼ÕÇ㸮»À ¸öÅë
  • body of pancreas
    ÃéÀå ¸öÅë, Ãéü
  • body of stomach
    À§ ¸öÅë
  • body of tongue
    Çô ¸öÅë, ¼³Ã¼
  • body part
    ¸öÅë ºÎºÐ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á